Clinical and toxicological consequences of the inductive potential of ethanol
- U. KlotzAffiliated withDr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Auerbachstrasse 112, D-70376 Stuttgart, Germany Tel: +49-711-8101-3702; Fax: +49-711-85 92 95
- , E. AmmonAffiliated withDr. Margarete Fischer-Bosch-Institut für Klinische Pharmakologie, Auerbachstrasse 112, D-70376 Stuttgart, Germany Tel: +49-711-8101-3702; Fax: +49-711-85 92 95
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Variability in drug metabolism is an important factor that accounts for individual responsiveness to xenobiotics. Enzyme induction which leads to a more rapid elimination of foreign compounds and to a more extensive formation of potentially active metabolites significantly contributes to large interindividual variability in drug effects.
Ethanol is consumed worldwide in tremendous amounts and is an effective inducer of hepatic drug metabolism, especially involving pathways accomplished by the CYP2E1 isoform of the cytochrome P-450 (CYP) superfamily. Therefore, whenever xenobiotics that are substrates of CYP2E1, such as chlorzoxazone, paracetamol (acetaminophen), halothane, enflurane, methoxyflurane, sevoflurane and many organic solvents (e.g. aniline, trichloroethylene), are taken by an individual who is also chronically consuming ethanol, the accelerated metabolism of these agents and their clinical impact (e.g. decrease in drug activity) and toxicological impact (accumulation of active metabolites) have to be considered.
Consequently, in the assessment of drug disposition and action the history of ethanol intake should be carefully evaluated.
- Clinical and toxicological consequences of the inductive potential of ethanol
European Journal of Clinical Pharmacology
Volume 54, Issue 1 , pp 7-12
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Key words Ethanol
- CYP2E1 Induction
- Industry Sectors